Liver: Asprosin - new hormone involved in hepatic glucose release.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed.

1. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.Scientific reports · 2019
   Trial
2. The Asp-Encoding Gene FBN1 Mediates Cold Adaptation in Sunite Sheep by Reprogramming Adipocyte Differentiation Towards Thermogenesis.Cells · 2026
   Article
3. Metformin's impact on asprosin and FBN1 expression: Potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats.Current research in pharmacology and drug discovery · 2025
   Article
4. Development of a mix-and-read assay for human asprosin using antibody-oligonucleotide probes and thermofluorimetric analysis.Analytical methods : advancing methods and applications · 2024
   Article
5. Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling.Immunity, inflammation and disease · 2023
   Article
6. Acute effect of moderate and high-intensity interval exercises on asprosin and BDNF levels in inactive normal weight and obese individuals.Scientific reports · 2023
   Article
7. Angiogenesis-Browning Interplay Mediated by Asprosin-Knockout Contributes to Weight Loss in Mice with Obesity.International journal of molecular sciences · 2022
   Article
8. Asprosin, a novel therapeutic candidate for painful neuropathy: an experimental study in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2022
   Article
9. The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases.Frontiers in physiology · 2022
   Review
10. Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue.The Journal of endocrinology · 2021
    Article
11. Asprosin is associated with anorexia and body fat mass in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
12. The role of Asprosin in patients with dilated cardiomyopathy.BMC cardiovascular disorders · 2020
    Article
13. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus.Journal of diabetes investigation · 2020
    Article
14. [Expression, purification and functional assessment of asprosin inclusion body].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
15. Aerobic Exercise Training Decreases Hepatic Asprosin in Diabetic Rats.Journal of clinical medicine · 2019
    Article
16. Serum asprosin levels and bariatric surgery outcomes in obese adults.International journal of obesity (2005) · 2019
    Article
17. Cytokines and Abnormal Glucose and Lipid Metabolism.Frontiers in endocrinology · 2019
    Review
18. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity.International journal of endocrinology · 2019
    Article
19. Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up.Obesity surgery · 2018
    Article
20. Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice.Frontiers in pharmacology · 2018
    Article

Corrections and comments

• Comment on
  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as